Psoriasis – Unmet Need – Detailed, Expanded Analysis : Moderate To Severe Psoriasis

With a drug-treated population of about 2.5 million people in the United States and EU5, the moderate to severe psoriasis market has been a lucrative space for drug developers, resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of other biologics like the IL-12/23 inhibitor Stelara, IL-17 inhibitors such as Cosentyx and Taltz, and IL-23 inhibitors such as Tremfya and Skyrizi. Nonetheless, the early- and late-phase pipeline for moderate to severe psoriasis has several promising agents because drug developers realize that, despite multiple current treatments, novel agents are needed that can differentiate themselves on the attributes of efficacy, convenient delivery, and ability to treat a broad patient population.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for moderate to severe psoriasis?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
  • What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?

PRODUCT DESCRIPTION

Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European dermatologists fielded in December 2020

Key companies: AbbVie, Janssen, Amgen, Novartis, Eli Lilly, UCB

Key drugs: Humira, Stelara, Otezla, Cosentyx, Taltz, Tremfya, Skyrizi

Table of contents

  • Psoriasis - Unmet Need - Detailed, Expanded Analysis : Moderate To Severe Psoriasis
    • Executive Summary
      • Unmet Need - Moderate to Severe Psoriasis - Executive Summary - February 2021
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Moderate to Severe Psoriasis and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Dermatologists' Prescribing Decisions in Moderate to Severe Psoriasis
        • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Moderate to Severe Psoriasis: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Moderate to Severe Psoriasis: United States
        • Overall Performance of Key Therapies for Moderate to Severe Psoriasis: Europe
        • Mean Overall Performance of Key Therapies for Moderate to Severe Psoriasis: United States and Europe
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Moderate to Severe Psoriasis
        • Surveyed Dermatologistsu2019 Satisfaction with the Performance of Key Therapies for Moderate to Severe Psoriasis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Dermatologistsu2019 Satisfaction with the Performance of Key Therapies for Moderate to Severe Psoriasis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Psoriasis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Psoriasis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Psoriasis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Psoriasis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Psoriasis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Psoriasis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Moderate to Severe Psoriasis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Moderate to Severe Psoriasis: Europe
        • Key Findings: Unmet Need in Moderate to Severe Psoriasis and Related Indications
        • Surveyed Dermatologists' Ascribed Level of Unmet Need in Moderate to Severe Psoriasis and Related Indications: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need in Moderate to Severe Psoriasis and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Moderate to Severe Psoriasis Market and Emerging Therapy Insights
          • Opportunity: A Novel Agent Offering Improved Sustained Efficacy in Moderate to Severe Psoriasis
          • Opportunity: A Novel Agent Offering Efficacy in a Broad Patient Population
          • Opportunity: A Safe and Efficacious Oral Therapy
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
        • Attribute Importance and Part-Worth Utilities
          • Moderate to Severe Target Product Profile: Attribute Importance
          • PASI 90 response at week 16 (% of patients)
          • Maintenance of PASI 90 response at week 44 (% of patients)
          • Median time to PASI 90 response rate (weeks)
          • sPGA score of clear or almost clear skin (0 or 1) at week 16 (% of patients)
          • Rate of serious adverse events
          • Route and frequency of administration
          • Price / day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Moderate to Severe Psoriasis Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Moderate to Severe Psoriasis Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Moderate to Severe Psoriasis Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Experts Interviewed
        • Bibliography

    launch Related Market Assessment Reports